Commonwealth Equity Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Commonwealth Equity Services’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,259	Closed	-$54K	–	3907
2023 Q3	$54K	Hold	10,259	–	–	﹤0.01%	3651
2023 Q2	$98K	Sell	10,259 -260	-2%	-$2.89K	﹤0.01%	3573
2023 Q1	$115	Buy	10,519 +260	+3%	+$3.76K	﹤0.01%	3469
2022 Q4	$151K	Hold	10,259	–	–	﹤0.01%	3325
2022 Q3	$196K	Hold	10,259	–	–	﹤0.01%	3186
2022 Q2	$218K	Hold	10,259	–	–	﹤0.01%	3117
2022 Q1	$197K	Hold	10,259	–	–	﹤0.01%	3344
2021 Q4	$212K	Hold	10,259	–	–	﹤0.01%	3250
2021 Q3	$245K	Sell	10,259 -50	-0.5%	-$1.14K	﹤0.01%	3095
2021 Q2	$281K	Sell	10,309 -685	-6%	-$19.3K	﹤0.01%	2966
2021 Q1	$318K	Buy	+10,994	New	+$343K	﹤0.01%	2711

Other funds holding ARQT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Commonwealth Equity Services's ARQT Position: Q4 2023 in Review

Commonwealth Equity Services sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 10,259 shares — an estimated $54K sold.

Commonwealth Equity Services first reported a position in ARQT in Q1 2021 and held it in 11 quarters. The position peaked at $318K in Q1 2021. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

Commonwealth Equity Services reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
Commonwealth Equity Services sold 10,259 Arcutis Biotherapeutics shares in Q4 2023, an estimated $54K.
Commonwealth Equity Services first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 11 quarters.
Commonwealth Equity Services's Arcutis Biotherapeutics position peaked at $318K in Q1 2021.
133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Commonwealth Equity Services's 13F filing for Q4 2023, filed 6 Feb 2024.